Safety and Efficacy of Vanoxerine for Conversion of Atrial Fibrillation or Flutter to Normal Sinus Rhythm

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 104 participants.

Also called NCT01691313

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 104 participants (enrolled count) (from the registry)
Sponsor
Laguna Pharmaceuticals, Inc. (from the registry)
Registry
  • NCT NCT01691313
Other papers using this trial's data
  • COR-ART: A multicenter, randomized, double-blind, placebo-controlled dose-ranging study to evaluate single oral doses of vanoxerine for conversion of recent-onset atrial fibrillation or flutter to normal sinus rhythm Heart rhythm, 2015-06 DOI, PubMed 25684233

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Israel, Russia (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01691313. Randomized; quadruple masking; primary purpose treatment. Start 2012-11 (registry gives no type); primary completion 2013-09 (actual). Results posted on 2015-12-22.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety and Efficacy of Vanoxerine for Conversion of Atrial Fibrillation or Flutter to Normal Sinus Rhythm
Acronym
COR-ART
Condition
Symptomatic Atrial Fibrillation
Intervention (Drug)
Vanoxerine
Intervention (Drug)
Placebo
Lead sponsor
Laguna Pharmaceuticals, Inc. (class: industry)

Record details

Record id
cardio:ct-nct01691313
Content hash
0757320426091e38eac879e5d2009a208c980040ef7b38b70fe162701cbef8e2